301, Tatum Highlands Medical Associates PLLC, 26224 N Tatum Blvd 15A — Phoenix, Arizona

301, Tatum Highlands Medical Associates PLLC, 26224 N Tatum Blvd 15A is a clinical research site located in Phoenix, Arizona, United States 85253.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

301, Tatum Highlands Medical Associates PLLC, 26224 N Tatum Blvd 15A has participated in 1 clinical trials.

Therapeutic areas: Influenza.

Sponsors: Novartis Vaccines.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Phoenix

Browse all research sites in Arizona · View every site in Phoenix

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for 301, Tatum Highlands Medical Associates PLLC, 26224 N Tatum Blvd 15A?

301, Tatum Highlands Medical Associates PLLC, 26224 N Tatum Blvd 15A has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has 301, Tatum Highlands Medical Associates PLLC, 26224 N Tatum Blvd 15A conducted?

301, Tatum Highlands Medical Associates PLLC, 26224 N Tatum Blvd 15A has 1 clinical trials on record. Their work covers Influenza.

Is 301, Tatum Highlands Medical Associates PLLC, 26224 N Tatum Blvd 15A accredited by Crixeo Clinical Trials?

301, Tatum Highlands Medical Associates PLLC, 26224 N Tatum Blvd 15A has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about 301, Tatum Highlands Medical Associates PLLC, 26224 N Tatum Blvd 15A?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.